Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Warburg Said to Hire Goldman Sachs to Sell Bausch & Lomb

A Bausch & Lomb manufacturing facility in Greenville, South Carolina. Warburg Pincus plans to hire Goldman Sachs Group Inc. to look at the sale of Bausch & Lomb Inc.
A Bausch & Lomb manufacturing facility in Greenville, South Carolina. Warburg Pincus plans to hire Goldman Sachs Group Inc. to look at the sale of Bausch & Lomb Inc.

Dec. 12 (Bloomberg) -- Warburg Pincus LLC hired Goldman Sachs Group Inc. to explore the sale of its Bausch & Lomb Inc. eye-care company, said two people with knowledge of the matter.

Warburg may seek at least $10 billion for the business, said one of the people, who asked not to be named because the process is confidential. The asset may only fetch as much as $8 billion, said another person familiar with the deliberations.

Bausch & Lomb makes products from contact lenses and solutions to equipment used in eye surgery. Warburg Pincus bought the Rochester, New York-based company for $3.7 billion in September 2007 after the eye-products maker was marred by accounting errors, lawsuits and the recall of one of its contact lens solutions.

Goldman this month contacted health-care companies such as Sanofi, GlaxoSmithKline Plc and Merck & Co., one person said. Other companies, such as Abbott Laboratories, also will be contacted, according to that person.

Warburg Pincus had talked to financial advisers about taking Bausch & Lomb public, the person said. The New York-based private-equity firm chose Goldman Sachs to run a limited sales process, and if a buyer can’t be found Warburg Pincus may pursue an IPO, according to the person.

Before Bausch & Lomb was taken private, Advanced Medical Optics Inc., now owned by Abbott Park, Illinois-based Abbott, tried to buy the company in July 2007 with a $4.3 billion bid.

Hassan Role

Bausch & Lomb’s chairman Fred Hassan, who is also a managing director at Warburg Pincus, has a history as a dealmaker in the health-care industry. He engineered the $37 billion takeover in March 2000 of Monsanto Co. by Pharmacia & Upjohn, he sold Pharmacia to New York-based Pfizer Inc. for $58 billion in 2003, and led Schering-Plough Corp. when it was sold to Whitehouse Station, New Jersey-based Merck for $41 billion in 2009.

Created more than 40 years ago, Warburg Pincus has over $30 billion in assets under management, according to the firm’s website. Past investments include Dutch cable operator Ziggo BV and food-services company Aramark, the site shows.

“Bausch & Lomb is regularly contacted by companies with strategic interest in our company, and we continue to aspire to a return to the public markets in the future,” said Adam Grossberg, a spokesman for the eye-care company. “However, our focus remains on building the best global eye-health company, and therefore won’t comment further.”

Officials at Goldman Sachs, Warburg Pincus, Merck, Paris-based Sanofi and London-based Glaxo declined to comment. An Abbott representative didn’t return calls seeking comment about the possible sale.

To contact the reporters on this story: Jeffrey McCracken in New York at jmccracken3@bloomberg.net; Devin Banerjee in New York at dbanerjee2@bloomberg.net; Albertina Torsoli in Paris at atorsoli@bloomberg.net

To contact the editors responsible for this story: Jeffrey McCracken at jmccracken3@bloomberg.net; Phil Serafino at pserafino@bloomberg.net; Christian Baumgaertel at cbaumgaertel@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.